London, United Kingdom

Takaaki Matsuki

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Ucl Business Plc. Active years: 2023-2025.


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Takaaki Matsuki: Innovator in Retinal Disorder Treatments

Introduction

Takaaki Matsuki is a prominent inventor based in London, GB. He has made significant contributions to the field of medical science, particularly in the treatment of retinal disorders. His innovative work has the potential to improve the quality of life for many individuals affected by these conditions.

Latest Patents

Matsuki holds a patent for "Compositions and methods for treating retinal disorders." This invention focuses on the prevention and treatment of retinal disorders, including cone dystrophies and cone-rod dystrophies, with a particular emphasis on Achromatopsia. His work in this area showcases his commitment to advancing medical treatments and addressing critical health issues.

Career Highlights

Throughout his career, Takaaki Matsuki has been associated with UCL Business Plc, where he has collaborated with other experts in the field. His dedication to research and innovation has led to the development of groundbreaking solutions for retinal disorders. With a patent portfolio that includes 1 patent, Matsuki continues to be a key figure in medical research.

Collaborations

Matsuki has worked alongside notable colleagues such as Robin Ali and Alexander Smith. These collaborations have further enriched his research and contributed to the advancement of treatments for retinal disorders.

Conclusion

Takaaki Matsuki is a distinguished inventor whose work in treating retinal disorders has the potential to make a significant impact in the medical field. His innovative approaches and collaborations highlight the importance of research in developing effective treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…